Citius Oncology, Inc. (NASDAQ:CTOR - Get Free Report) shares dropped 2% during trading on Wednesday . The stock traded as low as $1.16 and last traded at $1.20. Approximately 54,300 shares traded hands during mid-day trading, a decline of 64% from the average daily volume of 150,861 shares. The stock had previously closed at $1.23.
Wall Street Analyst Weigh In
Separately, Maxim Group started coverage on Citius Oncology in a research note on Wednesday, November 27th. They set a "buy" rating and a $3.00 price objective on the stock.
Read Our Latest Research Report on Citius Oncology
Citius Oncology Stock Performance
The company has a debt-to-equity ratio of 0.08, a quick ratio of 0.08 and a current ratio of 0.34. The stock has a fifty day moving average of $1.15.
About Citius Oncology
(
Get Free Report)
Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma.
Recommended Stories
Before you consider Citius Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Citius Oncology wasn't on the list.
While Citius Oncology currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
